Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2425]

ESMO 2024: Immunotherapy shows promise for men with specific types of prostate cancer

ESMO 2024: Immunotherapy shows promise for men with specific types of prostate cancer

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer

ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC

ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC

ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers

ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers

ESMO 2024: Repeat immune checkpoint inhibitor therapy not recommended for advanced kidney cancer

ESMO 2024: Repeat immune checkpoint inhibitor therapy not recommended for advanced kidney cancer

Researchers identify factor that drives prostate cancer-causing genes

Researchers identify factor that drives prostate cancer-causing genes

Study solves testosterone’s paradoxical effects in prostate cancer

Study solves testosterone’s paradoxical effects in prostate cancer

Targeted cancer therapies: Getting radioactive atoms to accumulate in tumours

Targeted cancer therapies: Getting radioactive atoms to accumulate in tumours

Scientists working to understand why men with prostate cancer are at higher risk of Alzheimer’s

Scientists working to understand why men with prostate cancer are at higher risk of Alzheimer’s

Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer

Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent...

More from ecancer